Synthesis and in vitro antileishmanial activity of 5-substituted-2′- deoxyuridine derivatives

Bioorganic Chemistry

Volumn 33, Issue 6, 2005, Pages 439-447

  Peyron, Corinne ^a   Benhida, Rachid ^a   Bories, Christian ^b   Loiseau, Philippe M ^b  

^a CNRS   (France)

^b UNIVERSITÉ PARIS SUD   (France)

Author keywords

Antileishmanial activity; Nucleosides

Indexed keywords

3',5' DI O ACETYL 5 (N TERT BUTOXYCARBONYLINDOLYL 2) 2' DEOXYURIDINE; 3',5' DI O TOLOUYL 5 (INDOLYL 2) 2' DEOXYURIDINE; 3',5' DI O TOLOUYL 5 (N TERT BUTOXYCARBONYLINDOLYL 2) 2' DEOXYURIDINE; 5 (INDOLYL 2) 2' DEOXYURIDINE; 5 (N TERT BUTOXYCARBONYLINDOLYL 2) 2' DEOXYURIDINE; ANTILEISHMANIAL AGENT; DEOXYURIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; IC 50; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE; STRUCTURE ANALYSIS; SUBSTITUTION REACTION;

ANIMALIA; LEISHMANIA DONOVANI; MURINAE; THIA;

EID: 27944506869     PISSN: 00452068     EISSN: 10902120     Source Type: Journal    
DOI: 10.1016/j.bioorg.2005.07.001     Document Type: Article

References (22)

1. S. Sundar Med. Microbiol. Immunol. 190 2001 89 92
2. P. Marty, and E. Rosenthal Expert Opin. Pharmacother. 3 2002 1101 1108
3. J. Berman Curr. Opin. Infect. Dis. 16 2003 397 401
4. E. Rosenthal, and P. Marty J. Postgrad. Med. 49 2003 61 68
5. A.J. Coukell, and R.N. Brogden Drugs 55 1998 585 612
6. R. Patel Expert Opin. Pharmacother. 1 2000 475 488
7. P.R. Veerareddy, and V. Vobalaboina Drugs Today 40 2004 133 145
8. S.C. Croft, and V. Yardley Curr. Pharm. Des. 8 2002 319 342
9. M. Robert-Géro, F. Lawrence, P. Blanchard, N. Dodic, H. Malina, and A. Mouna D.T. Hart Antileishmanial Effect of Sinefungin and Its Derivatives in Leishmaniasis 1989 Plenum Publishing Co. New York 757
10. L. Moulay, M. Robert-Géro, S. Brown, M.C. Gendron, and F. Tournier Exp. Cell. Res. 226 1996 283 291
11. D.H.R. Barton, S.D. Géro, F. Lawrence, M. Robert-Géro, B. Quiclet-Sire, and M. Sammadi J. Med. Chem. 35 1992 63 67
12. The 3′,5′-di-O-tolouyl-5-(indolyl-2)-2′-deoxyuridine was obtained as a side product, see Section 2 for spectral data.
13. S. RaynaudLe Grandic, C. Fourneau, A. Laurens, C. Bories, R. Hocquemiller, and P.M. Loiseau Biomed. Pharmacother. 58 2004 388 392
14. J.K. Sille Angew. Chem., Int. Ed. Engl. 25 1986 508 524
15. P. Wgerinck, L. Kerremans, P. Class, R. Snoeck, P. Maudgal, E. De Clercq, and P. Herdewijn J. Med. Chem. 36 1993 538 543
16. A.J. Gutierrez, T.J. Terhorst, M.D. Matteucci, and B.C. Froehler J. Am. Chem. Soc. 16 1994 5540 5544
17. R. Benhida, F. Lecubin, J.-L. Fourrey, L.R. Castellanos, and L. Quinteros Tetrahedron Lett. 40 1999 5701 5703
18. The 5-iodo-protected 2′-deoxyuridine was prepared from 2′-deoxyuridine according to our previously described procedure: R. Benhida, P. Blanchard, and J.-L. Fourrey Tetrahedron Lett. 39 1998 6849 6852
19. J.J. Marr, and R.I. Berens K.P. Chang R.S. Bray Purine and Pyrimidine Metabolism in Leishmania in Leishmaniasis 1985 Elsevier Amsterdam 65
20. P.O. Ogbunude, M.H. Al-Jazer, and H.P. Baer Exp. Parasitol. 73 1991 369 375
21. G. Vasudevn, N.S. Carter, M.E. Drew, S.M. Beverley, M.A. Sanchez, A. Seyfang, B. Ullman, and S.M. Landfear Proc. Natl. Acad. Sci. USA 95 1998 9873 9878
22. M. Ghosh, and T. Mukherjee Mol. Biochem. Parasitol. 108 2000 93 99